Research programme: HIV peptide oral vaccines - National Cancer Institute/National Resilience
Alternative Names: Research programme: HIV peptide oral vaccines - NCI/National ResilienceLatest Information Update: 18 Jun 2021
At a glance
- Originator Nanotherapeutics; National Cancer Institute (USA)
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 02 Oct 2017 Nanotherapeutics is now called Ology Bioservices
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-infections in USA (PO)
- 13 Aug 2007 Preclinical trials in HIV infections in USA (PO)